Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-13

Clinical Trial Update: Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing the safety and tolerability of intravenous brivaracetam as adjunctive therapy for epilepsy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Briviact (brivaracetam)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2016-04-13